Skip to Main Content

Paper Details

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Cancer Chemother Pharmacol
19
2021
CD24, CD44, CD44+ CD24- "stem-cell-like" breast cancer cells, HER2, HER2-negative metastatic breast cancer, JAK1/2, JAK2, MBC, Patients, RP2D, Ruxolitinib, STAT3, anemia, breast cancer, neutropenia, paclitaxel, patients, ruxolitinib, triple-negative breast cancer, visceral disease
Author NameAffiliation
Meredith M ReganDana-Farber Cancer Institute
Sara M TolaneyDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2